RUNX1 and acute lymphoblastic leukemia: Preclinical studies have revealed that cancer cells can be preferentially targeted by transcriptional inhibition, at least in part because they are more reliant than normal cells on high levels of super-enhancer (SE)-driven transcription [18, 19] mediated by specific oncogenic drivers, such as RUNX1 in acute lymphoblastic lymphoma (ALL) [20] and N-MYC in neuroblastoma [21].